Per Eystein Lønning

Haukeland University Hospital — Norway

Biochemistry, Genetics and Molecular Biology · Life Sciences

73h-index57.6kcitations629works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(201), Breast Cancer Treatment Studies(87), Cancer Genomics and Diagnostics(80), Epigenetics and DNA Methylation(71), Cancer-related Molecular Pathways(69)

Publications627 total

Improving Survival Models in Health Care by Balancing Imbalanced Cohorts: A Novel Approach
JCO Clinical Cancer Informatics·2026Open Access
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study
The Breast·2025Open Access
471P Impact of TP53 and HRD status on 5-year survival in TNBC treated with sequential neoadjuvant olaparib and high-dose cyclophosphamide/carboplatin (the PETREMAC trial)
Annals of Oncology·2025
Triple-Negative Breast Cancer on the Rise or…? [Letter]
Breast Cancer Targets and Therapy·2025Open Access
Abstract LB308: Rewiring of methylation during embryogenesis can seed cancer decades later
Cancer Research·2025
Comments on the paper “Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer” by Y. Chen et al.
International Journal of Cancer·2025Open Access
Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?
JCO Precision Oncology·2025· 1 cited
Germline variants in <i>CDKN2A</i> wild‐type melanoma prone families
Molecular Oncology·2025Open Access
The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy
BMC Cancer·2025Open Access
MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas
Clinical Epigenetics·2025· 2 citedOpen Access
Author response for "Germline variants in &lt;i&gt;CDKN2A&lt;/i&gt; wild‐type melanoma prone families"
2025
Improving survival models in healthcare: a novel matching approach
2024Open Access
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al
Breast Cancer Research and Treatment·2024
ASO Visual Abstract: Evaluating Combinations of Biological and Clinicopathologic Factors Linked to Poor Outcomes in Resected Colorectal Liver Metastasis: An External Validation Study
Annals of Surgical Oncology·2024
Evaluating Combinations of Biological and Clinicopathologic Factors Linked to Poor Outcomes in Resected Colorectal Liver Metastasis: An External Validation Study
Annals of Surgical Oncology·2024· 1 citedOpen Access
Interactions between neutrophils and macrophages harboring gram-negative bacteria promote obesity-associated breast cancer
2024Open Access
Germline variants in patients diagnosed with pediatric soft tissue sarcoma
Acta Oncologica·2024· 3 citedOpen Access
Hepatectomy <i>versus</i> systemic therapy for liver-limited <i>BRAF</i> V600E-mutated colorectal liver metastases: multicentre retrospective study
British journal of surgery·2024· 4 citedOpen Access
Rapid label expansion based on public-private collaboration in IMPRESS-Norway.
Journal of Clinical Oncology·2024
Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy
Cancer Research·2024· 1 cited
page 1 of 32Next →

Frequent Co-authors

Anne‐Lise Børresen‐Dale(11), Turid Aas(10), Jürgen Geisler(9), Charles M. Perou(8), Thérese Sørlie(8), Stephanie Geisler(8), Hilde Johnsen(7), David Botstein(6), Stian Knappskog(6), Gun Anker(6), Patrick O. Brown(5), Mitch Dowsett(5), Stefanie S. Jeffrey(4), Jonathan R. Pollack(4), Lars A. Akslen(4), Robert Tibshirani(4), Steinar Lundgren(4), E. Di Salle(4), Matt van de Rijn(3), Christian A. Rees(3)